Introduction: Uterine morcellation in minimally invasive surgery has recently come under scrutiny because of inadvertent dissemination of malignant tissue, including leiomyosarcomas commonly mistaken for fibroids. Identification of preoperative risk factors is crucial to ensure that oncologic care is delivered when suspicion for malignancy is high, while offering minimally invasive hysterectomies to the remaining patients. Objectives: The aim of this study was to characterize risk factors for uterine leiomyosarcomas by reviewing preoperative, intraoperative, and postoperative data with an emphasis on the presence of concurrent fibroids. Methods: A retrospective case-control study of women undergoing hysterectomy with pathologic diagnosis of uterine leiomyosarcoma at a tertiary care center between January 2005 and April 2014. Results: Thirty-one women were identified with leiomyosarcoma and matched to 124 controls. Cases with leiomyosarcoma were more likely to have undergone menopause and to present with larger uteri (19-vs 9-week sized), with the most common presenting complaint being a pelvic mass (35.5% vs 8.9%). Controls were ten times more likely to have undergone a tubal ligation (30.6% vs 3.2%). Endometrial sampling detected malignancy preoperatively in only 50% of cases. Leiomyosarcomas were more commonly present when pelvic masses were identified in addition to fibroids on preoperative imaging. Most leiomyosarcoma cases (77.4%) were performed by oncologists via an abdominal approach (83.9%), with only 2 of 31 leiomyosarcomas being morcellated. Comparative analysis of preoperative imaging and postoperative pathology showed that in patients with leiomyosarcoma, fibroids were misdiagnosed 58.1% of the time, and leiomyosarcomas arose directly from fibroids in only 6.5% of cases. Conclusions: Leiomyosarcoma risk factors include older age/postmenopausal status, enlarged uteri of greater than 10 weeks, and lack of previous tubal ligation. Preoperative testing failed to definitively identify leiomyosarcomas, although the presence of synchronous pelvic masses in fibroid uteri should raise clinical suspicion. Given the difficulty of preoperative identification, future efforts should focus on the development of safer minimally invasive techniques for uterine morcellation.
U
terine leiomyosarcoma (LMS) is an aggressive smooth muscle tumor with poorly understood origins and risk factors. 1 Although rare, with a prevalence of only 1 of 498 to 1 of 568 in women undergoing hysterectomy, LMS recently gained widespread attention when the Food and Drug Administration issued warnings regarding the use of power morcellation devices to extract uterine specimens. 2 Undiagnosed LMS is of particular concern because of the risks of disseminating cellular debris within the peritoneal cavity resulting in higher recurrence and death rates. 3Y9 Despite the clear advantages of minimally invasive hysterectomies over the abdominal approach, which include decreased rates of blood transfusions, venous thromboembolic events, wound infections, hernias, and death, 10 this warning has led to increased restrictions on power morcellation, leaving surgeons searching for ways to identify ''at-risk patients'' preoperatively. However, similarities in clinical presentation have limited our ability to definitively distinguish LMS from benign leiomyomas, despite use of tumor marker testing, various imaging modalities, and endometrial sampling. 11Y15 Previous studies have suggested that increasing age, African American race, and hormone replacement therapy (HRT) are associated with higher rates of LMS; however, the origin of LMS and its relationship to benign leiomyomas are poorly understood. 16, 17 It is now believed that only a minority of LMS cases arise in the background of fibroids, yet we lack adequate preoperative risk stratification and testing to reliably distinguish LMS from fibroids before hysterectomy. 18, 19 This case-control study aims to define preoperative, intraoperative, and postoperative characteristics of LMS encountered at our tertiary academic institution during a 9-year period compared with controls. Identification of LMS-associated characteristics may assist in risk stratification that would allow for safe, selective use of uterine morcellation in patients undergoing minimally invasive hysterectomies.
MATERIALS AND METHODS
A retrospective case-control chart review was performed of all patients given a diagnosis of LMS at Magee-Womens Hospital of UPMC between January 2005 and April 2014. Cases were identified through the pathology database and included only patients with a diagnosis of uterine LMS undergoing primary surgical management. Exclusion criteria included recurrent LMS, LMS of alternate soft tissue (not uterine primary), or surgery performance at another institution. Leiomyosarcoma cases were temporally matched in a standard statistical 1:4 ratio to control subjects consisting of the next four hysterectomies performed for any indication to ensure a diverse range of hysterectomies for comparison. Controls were purposefully not matched by any other criteria to capture the broadest constellation of preoperative presentation and testing, as well as concurrent pathology for comparison with LMS cases.
Chart reviews extracted preoperative, intraoperative, and postoperative data. Preoperative information included age at the time of surgery, gravity, parity, race, body mass index (BMI), tobacco use, menopausal status, history of HRT, tamoxifen use, cancer, chemotherapy, radiation, and previous pelvic surgery. In addition, we collected data on presenting symptoms, lactate dehydrogenase (LDH) serum values, imaging findings, endometrial sampling, and uterine size on physical examination. Operative information consisted of route of hysterectomy, specialty of primary surgeon, intraoperative consultations, length of surgery, estimated blood loss (EBL), performance of morcellation, and intraoperative complications. Finally, the pathology details were abstracted.
The University of Pittsburgh Institutional Review Board approved this study.
Statistical Methods
Descriptive statistics are reported for both patient cohorts. Continuous variables are presented as means and standard deviations. Categorical variables are presented as percentages. For comparisons between cases and controls, the nonparametric Mann-Whitney U test was used for all continuous variables because of small group sizes, and the W 2 or Fisher exact test (as appropriate) was used for categorical variables. SPSS Statistics version 22.0 (IBM Corp, Armonk, NY) was used for all analyses. A P value of less than 0.05 was considered statistically significant.
RESULTS
Of 9378 hysterectomies performed at Magee-Womens Hospital between January 2005 and April 2014, 31 patients with pathology-confirmed LMS met criteria. One hundred twenty-four controls were identified as described previously for comparative analysis.
Population demographics were consistent among cases and controls with the exception of age and menopausal status; patients with LMS were older and more likely to be postmenopausal (Table 1) . No other differences were identified between the groups in BMI, gravity, parity, tobacco use, race, HRT, tamoxifen use, or history of cancer, chemotherapy, and pelvic radiation. Previous surgical history was remarkable for 30.6% of controls having undergone a bilateral tubal ligation (BTL) compared with only 3.2% of patients with LMS (P = 0.002) ( Table 2) .
The primary presenting complaints in LMS cases included pelvic masses, abnormal uterine bleeding (AUB), and abdominal/pelvic pain (Table 3) . Controls were more likely to report pelvic organ prolapse (POP), with no patients with LMS presenting with prolapse.
Furthermore, 51.6% of patients with LMS had preoperative endometrial sampling (vs 50.8% in controls, P = 0.560) ( Table 4) . Of the 15 patients with sufficient endometrial sampling, 7 patients (46.7%) had pathology consistent with malignancy, of which 5 had either a preoperative sarcoma or LMS diagnosis. Only 14.3% of controls had malignancy on endometrial sampling (P = 0.005). Uterine size on physical examination was significantly larger in LMS (mean, 19.0 vs 9.2 weeks of gestation; P G 0.001). Small numbers of both case and control patients had LDH serum testing with no difference in percentage of patients with abnormal values (48.4% vs 31.3%, P = 0.473).
All patients with LMS (n = 31) had preoperative imaging compared with 76.6% of control subjects (n = 95) ( Table 5) . Imaging modalities included transvaginal ultrasound, computed tomography, magnetic resonance imaging (MRI), or others Table 6 ). There were no differences in these additional imaging findings when no concurrent fibroids were identified. However, in the presence of fibroids, these concurrent pathologies were solely recognized in the group with LMS (P G 0.001).
Operative details are summarized in Table 7 . The most common surgical route in LMS cases was via abdominal hysterectomy (83.9%), with the rest being performed either laparoscopically (12.9%) or vaginally (3.2%) (P G 0.001). Controls had 62.9% of hysterectomies performed minimally invasively, whereas 37.1% were performed via an abdominal approach. Furthermore, 77.4% of LMS cases were performed by a gynecologic oncologist with referral prompted primarily by preoperative diagnosis of malignancy or concerning imaging findings. Intraoperative and preoperative consultation with an oncologist occurred in an additional 6 patients, leaving only 1 patient who was solely managed by a general gynecologist. Controls had less intraoperative consultations (general surgery, n = 2; urology, n = 1; P = 0.002) and had 3 planned joint cases with plastic surgery or maternal fetal medicine. Lower urinary tract injuries were the most common complication (n = 3) in LMS cases, whereas hemorrhage/ transfusion was more common in the control group (n = 4), although EBL was significantly higher in LMS cases (828 mL) than controls (253 mL) (P G 0.001). No difference in operative time was observed. With regard to specimen retrieval, only 2 of the 31 LMS cases were morcellated compared with 24 controls (P = 0.083). One LMS was vaginally morcellated at the time of the vaginal hysterectomy, and the second was power morcellated at the time of the laparoscopic supracervical hysterectomy. Uterine weight was significantly greater in LMS cases (1833 vs 234 g, P G 0.001).
Postoperative pathology examination revealed that nearly all patients with LMS (96.8%) had other reported pathology on Description of preoperative laboratory, pathology, and physical examination testing in subjects with LMS versus controls.
n, number of subjects with applicable testing performed. Description of preoperative imaging including number and types of imaging modalities, as well as presence of benign leiomyomas and coexisting other pathology in subjects with LMS versus controls.
Adx, adnexal; n, number of subjects with imaging.
the final specimen other than fibroids (Supplemental Table 1 , http://links.lww.com/IGC/A447). However, no differences were noted between cases and controls in rates of endometriosis and cervico-or tubo-ovarian or ovarian pathology. Controls were more likely to have adenomyosis (41.9% vs 19.4%, P = 0.020), whereas patients with LMS had increased numbers of endometrial polyps (32.3% vs 14.5%, P = 0.022). Interestingly, one LMS was reported to be arising from a polyp with only superficial endometrial involvement. Given that LMS have also been proposed to arise from fibroids, we performed subgroup analyses on these cases.
Only 12 patients with LMS (38.7%) versus 44 control patients (46.3%) had benign leiomyomas reported on their pathology, and only 2 pathology reports specifically commented that the LMS was arising from a leiomyoma (6.5% of all cases). Moreover, because LMS are frequently misidentified preoperatively for benign fibroids (and vice versa), we performed further correlative studies comparing preoperative imaging versus postoperative pathological examination to assess the accuracy of fibroid detection in the presence and absence of LMS (Tables 8Y10) . Thirty-seven of 44 control patients (84.1%) who had fibroids on imaging had correlative fibroids on the final pathology, in contrast to LMS cases where correlation was noted only in 5 of 16 subjects (31.3%) (P G 0.001) ( Table 8) . Overall discordance between imaging and pathology for the presence or absence of fibroids was observed in 58.1% (n = 18/31) of LMS cases in contrast to only 24.5% (n = 23/94) of controls (P G 0.001). Although there was no statistical difference in the absolute presence or absence of fibroids between cases and controls on imaging or final pathology, in LMS cases, mean maximum fibroid size was significantly larger on preoperative imaging than on postoperative pathology (Table 9 ). However, when adjusted for the preoperatively Analysis of presence, number, and maximum-sized fibroid on preoperative imaging compared with postoperative pathological examination in subjects with LMS versus controls.
n, number of subjects with imaging and intact pathology specimen available for review (ie, unmeasured fibroids or morcellated specimen excluded for size measurements). n, number of subjects with imaging.
misdiagnosed fibroids in LMS, which in most LMS uteri represented a single fibroid, this trend was no longer statistically different (Table 10 ).
DISCUSSION
Our review identifies and matches 31 cases of pathologyconfirmed uterine LMS to control hysterectomies during the course of 9 years at our institution. In this time frame, 9378 hysterectomies were performed translating to an incidence of 1 of 303 (0.3%), which is consistent with published rates. 2 Only 2 of the 31 LMS cases were inadvertently morcellated. This is comparable with the rate of morcellated LMS in other recent studies. 20Y22 It is important to differentiate the risk of LMS from the risk of inadvertent morcellation of LMS. In our series, the rate of LMS in patients undergoing hysterectomy was 31 of 9378 (0.3%), whereas the risk of inadvertently morcellating LMS was 2 (0.02%) of 9378. With appropriate patient selection, the risk of morcellating occult LMS seems to be quite low.
With recently implemented restrictions on power morcellation, redirecting focus toward identification of risk factors associated with LMS has become the key in continuing to safely offer patients minimally invasive hysterectomies. Patient demographics of increasing age and postmenopausal status did seem to be risk factors, as suggested by previous authors. 16, 23 African American race has been associated with increased rates of LMS; however, this was not demonstrated in our series. 16, 23 Previous studies have demonstrated that previous radiotherapy does not seem to be a risk factor for LMS (unlike typical sarcomas), which is supported by our cohort in which no patients had a history of pelvic radiation. 24, 25 Hormone replacement therapy was not shown in the Women's Health Initiative to increase rates of nonendometrial uterine cancers, and indeed, no statistical difference was noted in our case series. 17 Interestingly, in contrast to controls who underwent BTL near national rates, only 1 of 31 (3.2%) women in the group with LMS had a BTL. 26 Salpingectomy and BTL have been documented to decrease the odds of ovarian/fallopian tube cancer, as well as reduce mortality in high-grade endometrial cancer. 27, 28 Additional studies may support opportunistic salpingectomies as LMS risk-reducing strategy at the time of permanent sterilization or other adnexal surgeries.
Although no definitive presenting complaint identified LMS, a higher trend toward pelvic masses and AUB raised clinical suspicion, whereas those with POP lowered it. No cases of LMS in 1196 women undergoing hysterectomy with concurrent POP procedures were noted at our institution. Although still at risk for other incidentally encountered non-LMS cancers (0.25%), patients undergoing urogynecologic procedures seem to represent an extremely low-risk cohort that would benefit from morcellation given higher medical comorbidities observed in this usually older patient population. 29 To improve preoperative diagnosis of LMS, a variety of testing strategies have been evaluated. Combination of LDH levels and dynamic MRI with apparent diffusion coefficient value carries sensitivities and specificities of 94% to 100% in differentiating LMS from benign leiomyoma. 12, 13 However, this is only useful in cases where clinical suspicion for LMS is already high with limited universal application for general preoperative screening. This is apparent in our series in which LDH values did not differ significantly between the 2 groups, and only a small fraction of patients with LMS underwent MRI. Similarly, little success has been demonstrated with endometrial sampling to detect LMS as would be expected unless the tumor had reached the endometrial surface. 14, 15 In our cohort, when sufficient endometrial sampling was performed, 46.7% were positive for malignancy, leaving 53.3% of patients with unrecognized high-grade malignancy before hysterectomy. We hypothesized that larger tumor size and presence of LVSI might increase the likelihood of positivity on endometrial sampling; however, this was unable to be demonstrated on further subanalysis (data not shown). Hence, negative endometrial sampling should not be a reassuring feature for preoperative risk stratification of candidates considered for uterine morcellation. Furthermore, although patients with LMS had larger uteri on pelvic examination (and pathological examination), large standard deviations suggest overlap with control uterine sizes. However, it should be noted that no LMS cases were observed in hysterectomies performed in uteri less than 10 weeks of gestation. This is particularly important for women undergoing supracervical procedures in which uterine morcellation may be required for tissue extraction.
Despite having similar clinical presentations and tissue derivations, previous molecular studies have demonstrated stark differences in biomarker and microRNA expression that suggest that leiomyoma and LMS have separate origins or at least alternate transformation pathways. 30, 31 In our study, only 6.5% of LMS cases seemed to be arising within a benign leiomyoma, and only 38.7% of patients had concomitant benign fibroids. These rates are low, which is consistent with other small studies that suggest that LMS rarely arises within benign leiomyomas. 18 Yet, these 2 discrete entities continue to be midsdiagnosed preoperatively. This discrepancy is likely largely fueled by the lack of imaging modalities to reliably differentiate these pathologies, as demonstrated in our series where 35.5% of preoperatively identified ''fibroids'' in LMS Analysis of maximum-sized fibroid depending on correspondence or discrepancy between preoperative (imaging) and postoperative (pathology) detection of fibroids in subjects with LMS versus controls.
*Numerator reflects number of patients with fibroids measured/ available for analysis.
n, number of subjects with available data/total number of subjects.
uteri likely represent malignancy. Furthermore, the size of the preoperatively misidentified fibroid did not differ significantly from those that were labeled correctly, hence further supporting this notion. Interestingly, a trend toward diagnosis of LMS was noted in those patients given a diagnosis of fibroids who also had synchronous adnexal, pelvic, or uterine masses. This finding may assist in preoperative risk stratification to avoid minimally invasive surgical approaches in patients with these imaging presentations. Furthermore, we tried to establish additional trends from postoperative pathological examination. Although most patients had other associated pathology on the final specimen, we were unable to identify a concomitant pelvic pathology consistently associated with LMS alone. However, 32.2% of LMS uteri had endometrial polyps, a rate much higher than controls (14.5%), and interestingly, one LMS arose directly from a polyp. Similarly, approximately one third of patients with LMS had expression of estrogen and progesterone receptors (37.5% and 31.3%, respectively) in their tumor (data not shown), suggesting a potential role of these hormones in the pathogenesis of LMS.
Weaknesses of this study are those inherent to a retrospective chart review, including missing or illegible data leading to limited data sets for some parameters and/or errors in data collection. For this reason, prestudy power analysis was also impossible to assess leading to the standardized 1:4 case-control match we chose for this hypothesis-generating retrospective study. Furthermore, given the nature of a retrospective review, there was a lack of standardized preoperative testing (LDH, endometrial sampling, type of imaging modality), which somewhat limits generalizations about the current testing strategies. In light of this, we purposefully did not match controls to LMS cases by criteria other than time to account for surgical practices, while avoiding missing risk factors that may help distinguish these two groups preoperatively. In particular, case-control matching based on criteria such as fibroids or uterine size would have meant that we could not evaluate these variables as risk factors for LMS and would have represented a skewed patient population for other variables. Strengths of the study include its large sample size and case-control nature, as well as an array of preoperative testing, which allowed us to identify numerous preoperative risk factors. In addition, we highlighted an important discrepancy in the imaging findings of LMS cases commonly mistaken for fibroids. We demonstrate that fibroids are misidentified in nearly two third of LMS cases and only rarely give rise to LMS.
In summary, given the current lack of definitive preoperative risk stratification to diagnose or differentiate LMS from benign leiomyomas, physicians need to counsel their patients on the potential risks of uterine morcellation if desiring to undergo minimally invasive surgery. In addition, with better preoperative risk assessment, these candidates electing for morcellation can be more suitably chosen in an attempt to further minimize risk of malignant dissemination. Future efforts should also be directed toward delineating safer methods for contained uterine morcellation for those patients electing to undergo minimally invasive hysterectomies. Until these techniques have been perfected, suspicious cases should be performed via abdominal hysterectomy by or under consultation of a gynecologic oncologist, and uterine morcellation should be discouraged.
